BACKGROUND: Common single-nucleotide polymorphisms (SNPs) that are associated with blood low-density lipoprotein (LDL) or high-density lipoprotein (HDL) cholesterol modestly affect lipid levels. We tested the hypothesis that a combination of such SNPs contributes to the risk of cardiovascular disease. METHODS: We studied SNPs at nine loci in 5414 subjects from the cardiovascular cohort of the Malmö Diet and Cancer Study. We first validated the association between SNPs and either LDL or HDL cholesterol and subsequently created a genotype score on the basis of the number of unfavorable alleles. We used Cox proportional-hazards models to determine the time to the first cardiovascular event in relation to the genotype score. RESULTS: All nine SNPs showed replication of an association with levels of either LDL or HDL cholesterol. With increasing genotype scores, the level of LDL cholesterol increased from 152 mg to 171 mg per deciliter (3.9 to 4.4 mmol per liter), whereas HDL cholesterol decreased from 60 mg to 51 mg per deciliter (1.6 to 1.3 mmol per liter). During follow-up (median, 10.6 years), 238 subjects had a first cardiovascular event. The genotype score was associated with incident cardiovascular disease in models adjusted for covariates including baseline lipid levels (P<0.001). The use of the genotype score did not improve the clinical risk prediction, as assessed by the C statistic. However, there was a significant improvement in risk classification with the use of models that included the genotype score, as compared with those that did not include the genotype score. CONCLUSIONS: A genotype score of nine validated SNPs that are associated with modulation in levels of LDL or HDL cholesterol was an independent risk factor for incident cardiovascular disease. The score did not improve risk discrimination but did modestly improve clinical risk reclassification for individual subjects beyond standard clinical factors. Copyright 2008 Massachusetts Medical Society.
BACKGROUND: Common single-nucleotide polymorphisms (SNPs) that are associated with blood low-density lipoprotein (LDL) or high-density lipoprotein (HDL) cholesterol modestly affect lipid levels. We tested the hypothesis that a combination of such SNPs contributes to the risk of cardiovascular disease. METHODS: We studied SNPs at nine loci in 5414 subjects from the cardiovascular cohort of the Malmö Diet and Cancer Study. We first validated the association between SNPs and either LDL or HDL cholesterol and subsequently created a genotype score on the basis of the number of unfavorable alleles. We used Cox proportional-hazards models to determine the time to the first cardiovascular event in relation to the genotype score. RESULTS: All nine SNPs showed replication of an association with levels of either LDL or HDL cholesterol. With increasing genotype scores, the level of LDL cholesterol increased from 152 mg to 171 mg per deciliter (3.9 to 4.4 mmol per liter), whereas HDL cholesterol decreased from 60 mg to 51 mg per deciliter (1.6 to 1.3 mmol per liter). During follow-up (median, 10.6 years), 238 subjects had a first cardiovascular event. The genotype score was associated with incident cardiovascular disease in models adjusted for covariates including baseline lipid levels (P<0.001). The use of the genotype score did not improve the clinical risk prediction, as assessed by the C statistic. However, there was a significant improvement in risk classification with the use of models that included the genotype score, as compared with those that did not include the genotype score. CONCLUSIONS: A genotype score of nine validated SNPs that are associated with modulation in levels of LDL or HDL cholesterol was an independent risk factor for incident cardiovascular disease. The score did not improve risk discrimination but did modestly improve clinical risk reclassification for individual subjects beyond standard clinical factors. Copyright 2008 Massachusetts Medical Society.
Authors: Amy I Lynch; John H Eckfeldt; Barry R Davis; Charles E Ford; Eric Boerwinkle; Catherine Leiendecker-Foster; Donna K Arnett Journal: Pharmacogenet Genomics Date: 2012-05 Impact factor: 2.089
Authors: Euan A Ashley; Atul J Butte; Matthew T Wheeler; Rong Chen; Teri E Klein; Frederick E Dewey; Joel T Dudley; Kelly E Ormond; Aleksandra Pavlovic; Alexander A Morgan; Dmitry Pushkarev; Norma F Neff; Louanne Hudgins; Li Gong; Laura M Hodges; Dorit S Berlin; Caroline F Thorn; Katrin Sangkuhl; Joan M Hebert; Mark Woon; Hersh Sagreiya; Ryan Whaley; Joshua W Knowles; Michael F Chou; Joseph V Thakuria; Abraham M Rosenbaum; Alexander Wait Zaranek; George M Church; Henry T Greely; Stephen R Quake; Russ B Altman Journal: Lancet Date: 2010-05-01 Impact factor: 79.321
Authors: Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar Journal: Ann Med Date: 2020-08-24 Impact factor: 4.709
Authors: Dilek Pirim; Xingbin Wang; Zaheda H Radwan; Vipavee Niemsiri; John E Hokanson; Richard F Hamman; M Michael Barmada; F Yesim Demirci; M Ilyas Kamboh Journal: J Lipid Res Date: 2013-11-09 Impact factor: 5.922
Authors: Carla A Ibrahim-Verbaas; Myriam Fornage; Joshua C Bis; Seung Hoan Choi; Bruce M Psaty; James B Meigs; Madhu Rao; Mike Nalls; Joao D Fontes; Christopher J O'Donnell; Sekar Kathiresan; Georg B Ehret; Caroline S Fox; Rainer Malik; Martin Dichgans; Helena Schmidt; Jari Lahti; Susan R Heckbert; Thomas Lumley; Kenneth Rice; Jerome I Rotter; Kent D Taylor; Aaron R Folsom; Eric Boerwinkle; Wayne D Rosamond; Eyal Shahar; Rebecca F Gottesman; Peter J Koudstaal; Najaf Amin; Renske G Wieberdink; Abbas Dehghan; Albert Hofman; André G Uitterlinden; Anita L Destefano; Stephanie Debette; Luting Xue; Alexa Beiser; Philip A Wolf; Charles Decarli; M Arfan Ikram; Sudha Seshadri; Thomas H Mosley; W T Longstreth; Cornelia M van Duijn; Lenore J Launer Journal: Stroke Date: 2014-01-16 Impact factor: 7.914